Julio Cesar Teixeira

List of Publications by Year
in descending order

62	5,905	304602	149623
papers	citations	22 h-index	56 g-index

63	63	63	4551
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, The, 2004, 364, 1757-1765.	6.3	1,435
2	Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet, The, 2009, 374, 301-314.	6.3	1,435
3	Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, The, 2012, 13, 89-99.	5.1	584
4	Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncology, The, 2012, 13, 100-110.	5.1	432
5	Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6Â·4 years. Lancet, The, 2009, 374, 1975-1985.	6.3	328
6	Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncology, The, 2015, 16, 775-786.	5.1	247
7	Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine. Human Vaccines and Immunotherapeutics, 2014, 10, 2147-2162.	1.4	207
8	Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine. Human Vaccines and Immunotherapeutics, 2012, 8, 390-397.	1.4	168
9	Efficacy of the human papillomavirus (HPV)â€16/18 AS04â€adjuvanted vaccine in women aged 15â€“25 years with and without serological evidence of previous exposure to HPVâ€16/18. International Journal of Cancer, 2012, 131, 106-116.	2.3	109
10	Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study. PLoS ONE, 2013, 8, e79260.	1.1	101
11	Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial. Vaccine Journal, 2015, 22, 361-373.	3.2	89
12	Prior human papillomavirusâ€16/18 AS04â€adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Postâ€hoc analysis from a randomized controlled trial. International Journal of Cancer, 2016, 139, 2812-2826.	2.3	74
13	Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized) Tj ETQq1 1 0.784314 rgBT /Ov	1.9	73
14	Prevalence and risk factors for cervical HPV infection and abnormalities in young adult women at enrolment in the multinational PATRICIA trial. Gynecologic Oncology, 2012, 127, 440-450.	0.6	55
15	Risk of Newly Detected Infections and Cervical Abnormalities in Women Seropositive for Naturally Acquired Human Papillomavirus Type 16/18 Antibodies: Analysis of the Control Arm of PATRICIA. Journal of Infectious Diseases, 2014, 210, 517-534.	1.9	45
16	Evaluation of Type Replacement Following HPV16/18 Vaccination: Pooled Analysis of Two Randomized Trials. Journal of the National Cancer Institute, 2017, 109, djw300.	3.0	43
17	Prevalence of Human Papillomavirus Infection and Associated Risk Factors in Young Women in Brazil, Canada, and the United States. International Journal of Gynecological Pathology, 2011, 30, 173-184.	0.9	35
18	Concomitant Cisplatin Plus Radiotherapy and Highâ€“Dose-Rate Brachytherapy Versus Radiotherapy Alone for Stage IIIB Epidermoid Cervical Cancer: A Randomized Controlled Trial. Journal of Clinical Oncology, 2014, 32, 542-547.	0.8	34

#	Article	IF	Citations
19	Incidence and duration of type-specific human papillomavirus infection in high-risk HPV-naÃ¯ve women: results from the control arm of a phase II HPV-16/18 vaccine trial. BMJ Open, 2016, 6, e011371.	0.8	34
20	Risk of first cervical HPV infection and pre-cancerous lesions after onset of sexual activity: analysis of women in the control arm of the randomized, controlled PATRICIA trial. BMC Infectious Diseases, 2014, 14, 551.	1.3	32
21	MMP-9/RECK Imbalance: A Mechanism Associated with High-Grade Cervical Lesions and Genital Infection by Human Papillomavirus and Chlamydia trachomatis. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1539-1547.	1.1	28
22	Mortality in pregnancy and the postpartum period in women with severe acute respiratory distress syndrome related to COVIDâ€19 in Brazil, 2020. International Journal of Gynecology and Obstetrics, 2021, 155, 475-482.	1.0	24
23	Estudo do impacto das deficiÃªncias de saneamento bÃ¡sico sobre a saÃºde pÃºblica no Brasil no perÃodo de 2001 a 2009. Engenharia Sanitaria E Ambiental, 2014, 19, 87-96.	0.1	23
24	Elimination of cervical cancer in lowâ€and middleâ€income countries: Inequality of access and fragile healthcare systems. International Journal of Gynecology and Obstetrics, 2021, 152, 7-11.	1.0	23
25	Analysis of Conservative Surgical Treatment and Prognosis of Microinvasive Squamous Cell Carcinoma of the Cervix Stage IA1: Results of Follow-Up to 20 Years. International Journal of Gynecological Cancer, 2017, 27, 357-363.	1.2	18
26	Is the HPV-test more cost-effective than cytology in cervical cancer screening? An economic analysis from a middle-income country. PLoS ONE, 2021, 16, e0251688.	1.1	18
27	Post Hoc Analysis of the PATRICIA Randomized Trial of the Efficacy of Human Papillomavirus Type 16 (HPV-16)/HPV-18 AS04-Adjuvanted Vaccine against Incident and Persistent Infection with Nonvaccine Oncogenic HPV Types Using an Alternative Multiplex Type-Specific PCR Assay for HPV DNA. Vaccine Journal, 2015, 22, 235-244.	3.2	16
28	Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol. BMC Public Health, 2020, 20, 576.	1.2	15
29	Cervical Cancer Registered in Two Developed Regions from Brazil: Upper Limit of Reachable Results from Opportunistic Screening. Revista Brasileira De Ginecologia E Obstetricia, 2018, 40, 347-353.	0.3	15
30	Organized, Population-based Cervical Cancer Screening Program: It Would Be a Good Time for Brazil Now. Revista Brasileira De Ginecologia E Obstetricia, 2016, 38, 161-163.	0.3	11
31	Use of interstitial brachytherapy in pelvic recurrence of cervical carcinoma: Clinical response, survival, and toxicity. Brachytherapy, 2019, 18, 146-153.	0.2	11
32	Is Diagnostic Hysteroscopy Safe for the Investigation of Type II Endometrial Cancer? A Retrospective Cohort Analysis. Journal of Minimally Invasive Gynecology, 2021, 28, 1536-1543.	0.3	11
33	Determinants of Acquisition and Clearance of Human Papillomavirus Infection in Previously Unexposed Young Women. Sexually Transmitted Diseases, 2019, 46, 663-669.	0.8	10
34	Systematic lymphadenectomy for intermediate risk endometrial carcinoma treatment does not improve the oncological outcome. European Journal of Obstetrics and Gynecology and Reproductive Biology: X, 2019, 3, 100020.	0.6	9
35	Organization of cervical cancer screening with DNAâ€“HPV testing impact on earlyâ€“stage cancer detection: a populationâ€“based demonstration study in a Brazilian city. The Lancet Regional Health Americas, 2022, 5, 100084.	1.5	9
36	Estimating the public health impact of a national guideline on cervical cancer screening: an audit study of a program in Campinas, Brazil. BMC Public Health, 2019, 19, 1492.	1.2	8

#	Article	IF	Citations
37	Postâ€'radiotherapy hysterectomy does not benefit females with cervical adenocarcinoma. Molecular and Clinical Oncology, 2020, 13, 1-1.	0.4	8
38	Long-term outcomes of concomitant cisplatin plus radiotherapy versus radiotherapy alone in patients with stage IIIB squamous cervical cancer: A randomized controlled trial. Gynecologic Oncology, 2021, 160, 379-383.	0.6	7
39	Brachytherapy for stage IIIB squamous cell carcinoma of the uterine cervix: survival and toxicity. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2010, 56, 37-40.	0.3	7
40	Primary melanoma of the uterine cervix figo stage III B. Sao Paulo Medical Journal, 1998, 116, 1778-1780.	0.4	7
41	School-based HPV Vaccination: The Challenges in a Brazilian Initiative. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 926-931.	0.3	7
42	Development of a Multiplex PCR Test with Automated Genotyping Targeting E7 for Detection of Six High-Risk Human Papillomaviruses. PLoS ONE, 2015, 10, e0130226.	1.1	6
43	Cervical cancer in women under 25Âyears of age and outside the screening age: Diagnosis profile and longâ€term outcomes. International Journal of Gynecology and Obstetrics, 2021, 154, 150-156.	1.0	6
44	Diagnosis, treatment and survival of uterine sarcoma: A retrospective cohort study of 122 cases. Molecular and Clinical Oncology, 2020, 13, 81.	0.4	5
45	Endocervical gastric-type adenocarcinoma, an unrelated HPV tumour: difficulties in screening and diagnosis. BMJ Case Reports, 2017, 2017, bcr-2017-219724.	0.2	4
46	Stage and histology of cervical cancer in women under 25 years old. Journal of Gynecologic Oncology, 2019, 30, e55.	1.0	4
47	Cervical Cancer Screening with HPV Testing: Updates on the Recommendation. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 264-271.	0.3	4
48	HPV Vaccines: Separating Myths from Reality. Revista Brasileira De Ginecologia E Obstetricia, 2019, 41, 417-418.	0.3	3
49	Conservative treatment of microinvasive squamous cell carcinoma of the cervix stage IA1: Defining conization height to an optimal oncological outcome. PLoS ONE, 2021, 16, e0253998.	1.1	3
50	Incidence rates and temporal trends of cervical cancer relating to opportunistic screening in two developed metropolitan regions of Brazil: a population-based cohort study. Sao Paulo Medical Journal, 2019, 137, 322-328.	0.4	3
51	Maternal Deaths from COVID-19 in Brazil: Increase during the Second Wave of the Pandemic. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 567-572.	0.3	3
52	Microinvasive Adenocarcinoma of the Cervix in a Young Woman Vaccinated Against Human Papillomavirus. Journal of Lower Genital Tract Disease, 2014, 18, E50-E54.	0.9	2
53	Compulsory Vaccination: The Limit between Public and Private. Revista Brasileira De Ginecologia E Obstetricia, 2020, 42, 785-786.	0.3	1
54	Malignant Uterine Neoplasms Attended at a Brazilian Regional Hospital: 16-years Profile and Time Elapsed for Diagnosis and Treatment. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 137-144.	0.3	1

#	Article	IF	Citations
55	HPV Vaccination and Screening with High-Performance Test: Brazilian Evidence. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 885-886.	0.3	1
56	Safety of Conservative Management of High-Grade Squamous Intraepithelial Lesion in Women Under 30 Years Old. Women S Health Reports, 2022, 3, 601-607.	0.4	1
57	Detection of High-Risk Human Papillomavirus in Cervix Sample in an 11.3-year Follow-Up after Vaccination against HPV 16/18. Revista Brasileira De Ginecologia E Obstetricia, 2017, 39, 408-414.	0.3	0
58	Vaccination in women with cancer. Revista Brasileira De Ginecologia E Obstetricia, 2021, 43, 150-154.	0.3	0
59	Cervical cancer in women under 25 years old registered in a regional referral hospital: an 18-year evolutive analysis. , 0, , .		0
60	Post-radiotherapy hysterectomy does not benefit females with cervical adenocarcinoma. Molecular and Clinical Oncology, 2020, 13, 92.	0.4	0
61	The value of the endocervical margin status in LEEP: analysis of 610 cases. Archives of Gynecology and Obstetrics, 2022, , .	0.8	0
62	Human papillomavirus vaccination for adult women. Revista Brasileira De Ginecologia E Obstetricia, 2022, 44, 631-635.	0.3	0